Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 1 of 1
Full-Text Articles in Life Sciences
Efficacy Of Allogeneic Hematopoietic Cell Transplantation In Patients With Chronic Phase Cml Resistant Or Intolerant To Tyrosine Kinase Inhibitors, Farah Yassine, Tea Reljic, Muhamad Alhaj Moustafa, Madiha Iqbal, Hemant S. Murthy, Ambuj Kumar, Mohamed A. Kharfan-Dabaja
Efficacy Of Allogeneic Hematopoietic Cell Transplantation In Patients With Chronic Phase Cml Resistant Or Intolerant To Tyrosine Kinase Inhibitors, Farah Yassine, Tea Reljic, Muhamad Alhaj Moustafa, Madiha Iqbal, Hemant S. Murthy, Ambuj Kumar, Mohamed A. Kharfan-Dabaja
Hematology/Oncology and Stem Cell Therapy
Approximately 15-20% of chronic myeloid leukemia (CML) patients fail tyrosine kinase inhibitor (TKI) therapy secondary to resistance or intolerance. In the pre-TKI era, front-line allogeneic hematopoietic cell transplantation (alloHCT) represented the standard approach for patients with chronic phase-CML (CP-CML) who were deemed fit to tolerate the procedure and had a human leukocyte antigen compatible donor available. Currently, CP-CML patients are eligible for allo-HCT only if they fail more than one TKI and/or are intolerant to the drug. We performed a systematic review/meta-analysis of the available literature to assess the evidence regarding allo-HCT efficacy in CP-CML patients. Data from eligible studies …